Vantage logo

Go or no go? The FDA plays hardball

April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.

Vantage logo

Lilly jumps the gun with Dermira deal

The $1.1bn that Lilly is paying for lebrikizumab looks low ball, but competing against Dupixent will not come cheap. And then there are the Roche payments.

Vantage logo

Almirall spots an opportunity

The Spanish group shows again that there is a future in dermatology, but its Allergan deal really depends on the fate of one asset.